2024-01-11 17:00:00
Thermo Fisher to produce for Galapagos
The Dutch biotech has signed with Thermo Fisher for the production of its CAR-T drug candidate, which will be carried out in the San Francisco region (United States). Thermo Fisher will also be in charge of services associated with treatment such as logistics for this clinical program positioned in oncohematology. In November 2023, Galapagos had entrusted Landmark Bio with the manufacturing of its CAR-T for the Eastern United States, in Boston. A decentralized production network essential to progress on clinical trials and possible arrival of the treatment on the market.
Novartis joins SanReno
The Swiss laboratory got its hands on SanReno Therapeutics, a Chinese biotech specializing in treatments for kidney diseases. SanReno has rights in Greater China and Singapore to two late-stage products targeting immunoglobulin A nephropathy, or Berger’s disease. Atrasentan, an oral treatment, has already met its primary endpoint in phase III
while zigakibart, a subcutaneous monoclonal antibody, was authorized to begin phase III last October. Financial details of the operation have not been disclosed.
I will tell you
source
Iktos to work with Nerviano Medical Sciences
The French startup, specializing in AI for the design of new drugs, has just entered into a collaboration with the Italian biotech Nerviano Medical Sciences, positioned in oncology. The agreement will focus on kinases with the aim of identifying at least one promising molecule. Iktoswhich raised €15.50 million in May 2023, is increasing its collaborations in pharma with Kissei Pharmaceutical and Galapagos in particular.
Inventiva refinances to the tune of €25 million
The French biotech, specializing in NASH, announced the drawing of the second tranche, amounting to 25 million euros, of the loan granted by the EIB in May 2022. An operation made possible by the achievement of key milestones by Inventiveness. This drawdown will make it possible to continue financing its pivotal phase III clinical study evaluating lanifibranor against NASH, the results of which are planned to be published in the first half of 2026. With this financing, Inventiva ensures financial visibility until start of the third quarter of 2024.
CDMO: WuXi boosts its peptide manufacturing capacity
The Chinese CDMO Wuxi, through its WuXi AppTec division, is preparing to commission two new peptide manufacturing plants in China, in Changzhou and Taixing. In Changzhou, this is the manufacturer’s third dedicated peptide facility. In Taixing, the site is expected to be fully operational by 2025. With these investments, WuXi AppTec now has five API production sites, with solid-phase peptide synthesis capacity at 32,000 liters. “Our increased capacity is essential to accelerate drug development and ensure a reliable supply chain for our global partners”, said Minzhang Chen, CEO of WuXi AppTec. As of 2023, WuXi has supported approximately fifty peptide-focused projects, ranging from preclinical to commercial, and produced fifteen tons of peptide APIs and intermediates.
Selected for you
1704994601
#Galapagos #Novartis #Iktos #Inventiva #Wuxi